A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02477618
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
132
Enrollment
INDUSTRY
Sponsor class
Conditions
Super-Refractory Status Epilepticus
Interventions
DRUG:
SAGE-547
DRUG:
Placebo
Sponsor
Supernus Pharmaceuticals, Inc.